{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:55:46Z","timestamp":1767210946968},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T00:00:00Z","timestamp":1368144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0062736","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T21:07:47Z","timestamp":1368220067000},"page":"e62736","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy \u2013 A Randomized Cross-Over Study"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00870493","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Cheuk-Chun","family":"Szeto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie Ching-Ha","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Ming","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Bon","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip Kam-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,5,10]]},"reference":[{"key":"ref1","first-page":"709","article-title":"The commonest glomerulonephritis in the world: IgA nephropathy","volume":"245","author":"G D\u2019Amico","year":"1987","journal-title":"Q J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ndt\/17.1.64","article-title":"Prognostic Indicators of IgA Nephropathy in the Chinese \u2013 Clinical and Pathological Perspectives","volume":"17","author":"PKT Li","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(97)90456-X","article-title":"Histologic subclassification of IgA nephropathy: a clinico-pathologic study of 244 cases","volume":"29","author":"M Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"ref4","first-page":"265","article-title":"ACE inhibition reduce proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study","volume":"9","author":"G Maschio","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0272-6386(99)70416-6","article-title":"Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy","volume":"33","author":"D Russo","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1681\/ASN.V9122308","article-title":"The antiproteinuria effect of angiotensin antagonsim in human IgA nephropathy is potentiated by indomethacin","volume":"9","author":"N Perico","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"PK Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0272-6386(00)70054-0","article-title":"Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury","volume":"35","author":"P Ruggenenti","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitors","volume":"368","author":"JA Staessen","year":"2006","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","article-title":"Renin inhibition: what are the therapeutic opportunities?","volume":"16","author":"NDL Fisher","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren","volume":"42","author":"A Stanton","year":"2003","journal-title":"Hypertension"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"AH Gradman","year":"2005","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ndt\/15.5.637","article-title":"Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function","volume":"15","author":"P van Paassen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","article-title":"Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes","volume":"73","author":"F Persson","year":"2008","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0272-6386(00)70191-0","article-title":"Outcome of IgA nephropathy in adults graded by chronic histological lesions","volume":"35","author":"KF To","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"DC Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"IS Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"YC Ma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9149(03)00658-1","article-title":"Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure","volume":"92","author":"JW Fung","year":"2003","journal-title":"Am J Cardiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfr349","article-title":"Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study","volume":"27","author":"SC Tang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"HH Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2369-13-89","article-title":"Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease","volume":"13","author":"YT Chen","year":"2012","journal-title":"BMC Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/ndt\/gfh408","article-title":"The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy","volume":"19","author":"WY Leung","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.07590810","article-title":"Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy","volume":"6","author":"F Persson","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/ajh.2012.14","article-title":"Aliskiren and perindopril reduce the levels of transforming growth factor-\u03b2 in patients with non-diabetic kidney disease","volume":"25","author":"S Lizakowski","year":"2012","journal-title":"Am J Hypertens"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc10-0833","article-title":"Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy","volume":"33","author":"F Persson","year":"2010","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"JC6","DOI":"10.7326\/0003-4819-156-12-201206190-02009","article-title":"Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone","volume":"156","author":"L Moist","year":"2012","journal-title":"Ann Intern Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurjhf\/hfq212","article-title":"Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study","volume":"13","author":"H Krum","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/eurjhf\/hfq209","article-title":"Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)","volume":"13","author":"M Gheorghiade","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1470320311434818","article-title":"Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)","volume":"13","author":"HH Parving","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/14740338.2012.696608","article-title":"Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview","volume":"11","author":"F Angeli","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"HH Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"S Yusuf","year":"2008","journal-title":"N Engl J Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0062736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T19:02:07Z","timestamp":1645038127000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0062736"}},"subtitle":[],"editor":[{"given":"Christos","family":"Chatziantoniou","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,10]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0062736","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,10]]}}}